Semin Respir Crit Care Med 2013; 34(03): 297-304
DOI: 10.1055/s-0033-1348469
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Lung Transplantation for Cystic Fibrosis and Bronchiectasis

Paul A. Corris
1   Department of Respiratory Medicine, Institute of Transplantation and Institute of Cellular Medicine, Newcastle University and The Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle upon Tyne, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
02 July 2013 (online)

Abstract

Lung transplantation has become an excellent treatment option for patients with cystic fibrosis (CF) and bronchiectasis with very advanced lung disease. Despite the challenges that the CF patients present, survival is more favorable than that seen in patients with chronic obstructive pulmonary disease and pulmonary fibrosis. Although those CF and bronchiectasis patients with severe respiratory disease are often infected with organisms that display in vitro resistance to the commonly used antibiotics, they usually have successful outcomes with transplantation, which are reported to be the same as in those patients with less resistant bacteria. Preoperative synergy testing has been demonstrated to reduce the presence of postoperative bacteremia and empyema in patients with CF. Newer challenges include the increasing presence of nontuberculous mycobacteria and in particular the rapid grower Mycobacterium abscessus, for which patient-to-patient spread has been recently recognized. The increased recognition of gastroesophageal reflux offers challenges regarding when and to whom one should offer fundoplication. Most potential CF recipients have metabolic bone disease warranting treatment, especially with the significant loss of bone density seen in the first year after transplantation. Diabetes mellitus, renal dysfunction, and hypertension and their consequences remain common and are of increasing importance as median survival increases in excess of 10 years. With increased experience, more programs are now transplanting patients who require membrane oxygenator support in addition to noninvasive ventilation pretransplantation and the use of a membrane device in the awake patient principally to remove excessive CO2 and reduce acidemia is worthy of note (Novalung; Novalung GmbH, Heilbronn, Federal Republic of Germany). Many centers now take the view that an awake and ambulant patient receiving such support represents a more favorable option than an intubated patient. The limiting factor in lung transplantation remains the number of organs available. Efforts to increase the donor pool, such as low tidal volume ventilation, are effective in allowing a greater percentage of offered organs to be accepted. Perhaps the most encouraging development, however, is that of ex vivo lung perfusion. This permits not only the ability to measure the function of the lungs, something of great value for lungs from donors with circulatory death (donation after cardiac death), but also the potential to introduce lung repair and convert a nonusable lung to one that can be safely used for transplantation.

 
  • References

  • 1 Cystic Fibrosis Foundation Patient Registry. Annual data report to the center directors. Bethesda, MD: Cystic Fibrosis Foundation; 2008
  • 2 Hertz MI. The Registry of the International Society for Heart and Lung Transplantation—Introduction to the 2012 annual reports: new leadership, same vision. J Heart Lung Transplant 2012; 31 (10) 1045-1051
  • 3 Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004; 126 (2) 412-419
  • 4 Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 326 (18) 1187-1191
  • 5 Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML. Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. Am J Respir Crit Care Med 2002; 166 (12, Pt 1) 1550-1555
  • 6 Augarten A, Akons H, Aviram M , et al. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients. Pediatr Transplant 2001; 5 (5) 339-342
  • 7 Milla CE, Warwick WJ. Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 1998; 113 (5) 1230-1234
  • 8 Liou TG, Adler FR, Cahill BC , et al. Survival effect of lung transplantation among patients with cystic fibrosis. JAMA 2001; 286 (21) 2683-2689
  • 9 Kadikar A, Maurer J, Kesten S. The six-minute walk test: a guide to assessment for lung transplantation. J Heart Lung Transplant 1997; 16 (3) 313-319
  • 10 Venuta F, Rendina EA, Rocca GD , et al. Pulmonary hemodynamics contribute to indicate priority for lung transplantation in patients with cystic fibrosis. J Thorac Cardiovasc Surg 2000; 119 (4, Pt 1) 682-689
  • 11 Tuppin MP, Paratz JD, Chang AT , et al. Predictive utility of the 6-minute walk distance on survival in patients awaiting lung transplantation. J Heart Lung Transplant 2008; 27 (7) 729-734
  • 12 Flume PA, Mogayzel Jr PJ, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC. Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182 (3) 298-306
  • 13 Orens JB, Estenne M, Arcasoy S , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (7) 745-755
  • 14 Egan T, McCullough K, Murray S , et al. Risk factors for death after lung transplantation in the US. J Heart Lung Transplant 2003; 22 (1, Suppl): S146-S147
  • 15 Haja Mydin H, Corris PA, Nicholson A , et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transplant 2012; 2012 (1) ):135738. doi: 10.11552012/135738. Epub 2012 Jul 16
  • 16 Hadjiliadis D, Steele MP, Chaparro C , et al. Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 2007; 26 (8) 834-838
  • 17 Chaparro C, Maurer J, Gutierrez C , et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163 (1) 43-48
  • 18 Aris RM, Routh JC, LiPuma JJ, Heath DG, Gilligan PH. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164 (11) 2102-2106
  • 19 De Soyza A, McDowell A, Archer L , et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358 (9295) 1780-1781
  • 20 Alexander BD, Petzold EW, Reller LB , et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. . Am J Transplant 2008; 8 (5) 1025-1030
  • 21 Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of Burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178 (4) 363-371
  • 22 De Soyza A, Corris PA. Lung transplantation and the Burkholderia cepacia complex. J Heart Lung Transplant 2003; 22 (9) 954-958
  • 23 Levine SM. Transplant/Immunology Network of the American College of Chest Physicians. A survey of clinical practice of lung transplantation in North America. Chest 2004; 125 (4) 1224-1238
  • 24 McMenamin JD, Zaccone TM, Coenye T, Vandamme P, LiPuma JJ. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 2000; 117 (6) 1661-1665
  • 25 Olivier KN, Weber DJ, Wallace Jr RJ , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria, I: Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167 (6) 828-834
  • 26 Olivier KN, Weber DJ, Lee JH , et al; Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Nontuberculous mycobacteria, II: Nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 167 (6) 835-840
  • 27 Chernenko SM, Humar A, Hutcheon M , et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25 (12) 1447-1455
  • 28 Paradowski LJ. Saprophytic fungal infections and lung transplantation—revisited. J Heart Lung Transplant 1997; 16 (5) 524-531
  • 29 Helmi M, Love RB, Welter D, Cornwell RD, Meyer KC. Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. Chest 2003; 123 (3) 800-808
  • 30 Nash EF, Coonar AS, Durie PR, Singer LG, Keshavjee S, Chaparro C. Retrospective case control study comparing outcomes post-lung transplantationin cystic fibrosis patients with and without cystic fibrosis related liver cirrhosis [abstract]. J Heart Lung Transplant 2008; 27 (2) S138
  • 31 Souilamas R, Guillemain R, Boussaud V, Amrein C, Chevalier P, Fabiani JN. Combined lung and liver transplantation in patients with cystic fibrosis [abstract]. J Heart Lung Transplant 2007; 26 (2) S127
  • 32 Bravo C, Gispert P, Borro JM , et al; MITOS Study Group. Prevalence and management of gastrointestinal complications in lung transplant patients. Transplant Proc 2007; 39 (7) 2409-2412
  • 33 Hadjiliadis D, Duane Davis R, Steele MP , et al. Gastroesophageal reflux disease in lung transplant recipients. Clin Transplant 2003; 17 (4) 363-368
  • 34 Gilljam M, Chaparro C, Tullis E, Chan C, Keshavjee S, Hutcheon M. GI complications after lung transplantation in patients with cystic fibrosis. Chest 2003; 123 (1) 37-41
  • 35 Pokorny CS, Bye PT, MacLeod C, Selby WS. Antibiotic-associated colitis and cystic fibrosis. Dig Dis Sci 1992; 37 (9) 1464-1468
  • 36 Dallal RM, Harbrecht BG, Boujoukas AJ , et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235 (3) 363-372
  • 37 Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330 (4) 257-262
  • 38 Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile—associated diarrhea: a review. Arch Intern Med 2001; 161 (4) 525-533
  • 39 Binkovitz LA, Allen E, Bloom D , et al. Atypical presentation of Clostridium difficile colitis in patients with cystic fibrosis. AJR Am J Roentgenol 1999; 172 (2) 517-521
  • 40 Rivlin J, Lerner A, Augarten A, Wilschanski M, Kerem E, Ephros MA. Severe Clostridium difficile-associated colitis in young patients with cystic fibrosis. J Pediatr 1998; 132 (1) 177-179
  • 41 Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest 1996; 109 (5) 1176-1183
  • 42 Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest 2000; 117 (2) 476-481
  • 43 Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation 2001; 72 (7) 1251-1255
  • 44 Milla CE, Billings J, Moran A. Diabetes is associated with dramatically decreased survival in female but not male subjects with cystic fibrosis. Diabetes Care 2005; 28 (9) 2141-2144
  • 45 Dennis C, Caine N, Sharples L , et al. Heart-lung transplantation for end-stage respiratory disease in patients with cystic fibrosis at Papworth Hospital. J Heart Lung Transplant 1993; 12 (6, Pt 1) 893-902
  • 46 Madill J, Gutierrez C, Grossman J , et al; Toronto Lung Transplant Program. Nutritional assessment of the lung transplant patient: body mass index as a predictor of 90-day mortality following transplantation. J Heart Lung Transplant 2001; 20 (3) 288-296
  • 47 Singer LG, Brazelton TR, Doyle RL, Morris RE, Theodore J. International Lung Transplant Database Study Group. Weight gain after lung transplantation. J Heart Lung Transplant 2003; 22 (8) 894-902
  • 48 Robertson JM, Friedman EM, Rubin BK. Nasal and sinus disease in cystic fibrosis. Paediatr Respir Rev 2008; 9 (3) 213-219
  • 49 Detterbeck FC, Egan TM, Mill MR. Lung transplantation after previous thoracic surgical procedures. Ann Thorac Surg 1995; 60 (1) 139-143
  • 50 Curtis HJ, Bourke SJ, Dark JH, Corris PA. Lung transplantation outcome in cystic fibrosis patients with previous pneumothorax. J Heart Lung Transplant 2005; 24 (7) 865-869
  • 51 Elizur A, Sweet SC, Huddleston CB , et al. Pre-transplant mechanical ventilation increases short-term morbidity and mortality in pediatric patients with cystic fibrosis. J Heart Lung Transplant 2007; 26 (2) 127-131
  • 52 Meyer AL, Goerler H, Gottlieb J , et al. 66: Lung transplantation in patients on invasive ventilation and extracorporeal membrane oxygenation. J Heart Lung Transplant 2008; 27 (2, Suppl): S83
  • 53 Moran F, Bradley JM, Jones AP, Piper AJ. Non-invasive ventilation for cystic fibrosis. Cochrane Database Syst Rev 2007; (4) CD002769 . doi: 10.1002/14651858. Update in: Cochrane Database Syst Rev 2009;(1):CD002769.
  • 54 Orens JB, Boehler A, de Perrot M , et al; Pulmonary Council, International Society for Heart and Lung Transplantation. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22 (11) 1183-1200
  • 55 Mascia L, Pasero D, Slutsky AS , et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA 2010; 304 (23) 2620-2627
  • 56 Angel LF, Levine DJ, Restrepo MI , et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174 (6) 710-716
  • 57 Cypel M, Yeung JC, Liu M , et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364 (15) 1431-1440